Bellon Steven F. 4
4 · Foghorn Therapeutics Inc. · Filed Jan 25, 2024
Insider Transaction Report
Form 4
Bellon Steven F.
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-24$3.06/sh+110,000$336,600→ 110,000 totalExercise: $3.06Exp: 2034-01-23→ Common Stock (110,000 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.